05.07.2017 - 08:32:19

SYGNIS AG announces successful Completion of Acquisition of Innova Biosciences Ltd.


Press Release

SYGNIS AG announces successful Completion of Acquisition of Innova Biosciences Ltd.

Madrid, Spain, and Heidelberg, Germany, July 05, 2017 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) is pleased to announce that the Company has successfully completed its acquisition of Innova Biosciences Ltd.

SYGNIS AG paid EUR 10.8 million, consisting of EUR 8 million in cash and 2 million shares of SYGNIS AG as a contribution in kind. Depending on agreed performance indicators, the purchase price will also include up to 1.5 million shares issued as convertible bonds. To finance this transaction, SYGNIS successfully completed two capital increases in May 2017.

"We are delighted and proud to announce the completion of this acquisition which strengthens the SYGNIS brand and marks an important step towards leadership in the genomic and proteomic market," Dr. Heikki Lanckriet, CEO and CSO of SYGNIS, said. "This allows us to cater to our main goal of adding value for life science customers and significantly accelerate our growth. I would like to take the opportunity to commend both our teams, strategic partners and investors on the successful passing of this important milestone." "We are thrilled to be part of the SYGNIS Group, providing not only a great platform to grow our business internationally, but also giving us access to new target customers and markets. The fact that SYGNIS' and Innova's technologies are complementary allows us to capitalize on the resulting synergies. The new structure will enable us to grow our business even more quickly," Dr. Nick Gee, CTO of SYGNIS, said.

As part of the merger, Dr. Nick Gee, former CEO and CSO of Innova was appointed to Chief Technical Officer of SYGNIS. With a complementary portfolio covering the complete molecular biology value chain, SYGNIS is able to offer cutting-edge technology and services for all steps of the process, in particular by taking into account the synergistic Innova portfolio of over 300 products and the development of ad-hoc solutions to fit customers' needs.

For further information, please contact:SYGNIS AG Dr. Heikki Lanckriet CEO/CSO Phone: +44 1223 873 364 Email:

MC Services AG Raimund Gabriel Managing Partner Phone: +49 89 210228 0 Email:


SYGNIS AG specializes in the development and commercialization of proprietary technologies and offers a wide range of commercial products addressing key challenges in molecular biology. With the 2016 acquisition of Expedeon Holdings, Ltd. based in the UK, SYGNIS added a complementary proteomics product portfolio. Resulting from this significant expansion, SYGNIS' product portfolio now covers the entire workflow of molecular biology. In addition, SYGNIS acquired the profitable U.S.-based life sciences tools company C.B.S. Scientific in December 2016 to further expand its product offering. In June 2017, the Company acquired Innova Biosciences Ltd., world leading experts in easy-to-use, cutting-edge bioconjugation technologies and services. The products of SYGNIS Group are sold through a direct sales force and several distribution partners in Europe, the U.S. and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the U.S. as well as sales offices in Asia. The company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03).

### This document is not a securities prospectus and the information contained herein does not constitute an offer to sell or a solicitation of an offer to purchase any securities of SYGNIS AG in the Federal Republic of Germany nor under any other jurisdiction, in particular not where such kind of offer or solicitation is prohibited or lacks the required permission. Potential investors in securities of SYGNIS AG are asked to familiarize themselves with and to observe the respective restrictions.

The information in this document may not be disseminated outside the Federal Republic of Germany in particular not in the United States, to U.S. Persons (as defined in regulation S of the U.S. Securities Act of 1933) or to publications with a general circulation in the United States with the exception of a such disclosures or announcements outside the Federal Republic of Germany which have to be made under the respective mandatory law. Any person who fails to comply with these restrictions may violate the security laws of certain jurisdictions, in particular of the United States. Securities in SYGNIS AG are not publicly offered outside the Federal Republic of Germany.

Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###


Additional features:Document: title: Innova_Eng

05.07.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at

Language: English

Company: SYGNIS AG Waldhofer Str. 104 69123 Heidelberg

Germany Phone: +49 (0) 6221 3540 125 Fax: +49 (0) 6221 3540 127 E-mail: Internet: ISIN: DE000A1RFM03 WKN: A1RFM0 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange   End of News DGAP News Service

589577  05.07.2017 


Amazon wird sich schwarzärgern, aber …

… wir schenken Ihnen den Report „Börsenpsychologie - Markttechnik für Trader“ heute trotzdem kostenfrei. Normalerweise kostet der Report im Onlinehandel 39,99 Euro.

Sie können sich den genialen Report heute jedoch absolut kostenfrei sichern. Wir senden Ihnen den Report vollkommen KOSTENFREI zu.

Jetzt HIER klicken und dank richtigen Timing reich an der Börse werden!